Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.verified

APLS

Price:

$39.49

Market Cap:

$4.79B

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glome...[Read more]

Industry

Biotechnology

IPO Date

2017-11-09

Stock Exchange

NASDAQ

Ticker

APLS

The PE Ratio as of July 2024 (TTM) for Apellis Pharmaceuticals, Inc. (APLS) is -11.51

According to Apellis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -11.51. This represents a change of -41.38% compared to the average of -19.63 of the last 4 quarters.

Apellis Pharmaceuticals, Inc. (APLS) Historical PE Ratio (quarterly & annually)

How has APLS PE Ratio performed in the past?

The mean historical PE Ratio of Apellis Pharmaceuticals, Inc. over the last ten years is -9.57. The current -11.51 PE Ratio has changed 11.93% with respect to the historical average. Over the past ten years (40 quarters), APLS's PE Ratio was at its highest in in the December 2020 quarter at 13.86. The PE Ratio was at its lowest in in the March 2024 quarter at -27.63.

Quarterly (TTM)
Annual

Average

-9.57

Median

-7.28

Minimum

-23.53

Maximum

-5.35

Apellis Pharmaceuticals, Inc. (APLS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Apellis Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 102.70%

Maximum Annual PE Ratio = -5.35

Minimum Annual Increase = -76.81%

Minimum Annual PE Ratio = -23.53

Quarterly (TTM)
Annual
YearPE RatioChange
2023-13.4459.72%
2022-8.4157.33%
2021-5.35-57.10%
2020-12.47102.70%
2019-6.159.29%
2018-5.63-4.64%
2017-5.90-36.94%
2016-9.3671.49%
2015-5.46-76.81%
2014-23.53-63.28%

Apellis Pharmaceuticals, Inc. (APLS) Average PE Ratio

How has APLS PE Ratio performed in the past?

The current PE Ratio of Apellis Pharmaceuticals, Inc. (APLS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-9.07

5-year avg

-9.16

10-year avg

-9.57

Apellis Pharmaceuticals, Inc. (APLS) PE Ratio vs. Peers

How is APLS’s PE Ratio compared to its peers?

Apellis Pharmaceuticals, Inc.’s PE Ratio is greater than Prometheus Biosciences, Inc. (-81.93), less than Akero Therapeutics, Inc. (-8.96), greater than Immunovant, Inc. (-16.80), greater than Madrigal Pharmaceuticals, Inc. (-12.13), less than Day One Biopharmaceuticals, Inc. (-6.49), less than Mirati Therapeutics, Inc. (-5.32), less than Amylyx Pharmaceuticals, Inc. (-2.02), less than Terns Pharmaceuticals, Inc. (-7.88), less than X4 Pharmaceuticals, Inc. (-1.15), less than Inozyme Pharma, Inc. (-4.60), greater than Mereo BioPharma Group plc (-77.48), greater than Blueprint Medicines Corporation (-24.43), greater than Cerevel Therapeutics Holdings, Inc. (-16.85), less than Acumen Pharmaceuticals, Inc. (-3.28),

Build a custom stock screener for Apellis Pharmaceuticals, Inc. (APLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apellis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Apellis Pharmaceuticals, Inc. (APLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Apellis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Apellis Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Apellis Pharmaceuticals, Inc. (APLS)?

What is the highest PE Ratio for Apellis Pharmaceuticals, Inc. (APLS)?

What is the 3-year average PE Ratio for Apellis Pharmaceuticals, Inc. (APLS)?

What is the 5-year average PE Ratio for Apellis Pharmaceuticals, Inc. (APLS)?

How does the current PE Ratio for Apellis Pharmaceuticals, Inc. (APLS) compare to its historical average?